- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02101541
FIRM as a Stand-alone Procedure in the Treatment of Atrial Fibrillation
Focal Impulse and Rotor Modulation (FIRM) as a Stand-alone Procedure in the Treatment of Atrial Fibrillation
Studieoversikt
Detaljert beskrivelse
After a pilot/implementation study consisting of 10 patients with paroxysmal atrial fibrillation (AF); 20 patients with paroxysmal AF will be included in a within-patient trial. This study will be followed by a similar comparison in 20 patients with persistent or longstanding persistent AF.
The AF driving sources will be visualized by a novel sequential bi-atrial panoramic contact mapping technique. Unipolar signals will be recorded by a 64-polar basket catheter (FIRMap®, Topera. Inc.), then processed and the activation patterns visualized (RhythmView® 3D Electrophysiologic Mapping System, Topera, Inc.).
Focal impulse and rotor modulation (FIRM) will then be performed with standard irrigated radio frequency catheter ablation until rotor or focal impulse elimination is confirmed by repeat FIRM mapping.
Treatment efficacy will be assessed with continuous heart rhythm monitors (Reveal XT®, Medtronic, Minneapolis, USA) implanted 3 months prior to ablation, and freedom from AF defined as AF burden <1% at follow-up at 12, 24 and 30 months.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Oslo, Norge
- Dept. of Cardiology, Rikshospitalet - Oslo University Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Paroxysmal atrial fibrillation despite of at least one Class I or Class III antiarrhythmic drug and/or previous conventional ablation (pulmonary vein isolation).
- At least one episode of paroxysmal atrial fibrillation should be documented by rhythm strip, ECG or implanted monitor during the last 6 months prior to ablation.
Exclusion Criteria:
- Significant structural heart disease (including symptomatic coronary heart disease; prosthetic mitral or tricuspid valve; congenital heart disease where abnormality or its correction prohibits or increases the risk of ablation).
- Intracardiac thrombus, tumor or dense contrast on TEE.
- Contraindication to anticoagulant therapy (heparin, warfarin, dabigatran and rivaroxaban).
- Anaphylactic allergy to contrast media.
- Poor general health resulting from other disease.
- Inability or refusal to provide written informed consent for the study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: FIRM ablation
The first part of this within-patient trial investigate the efficacy of focal impulse and rotor modulation in 20 patients with paroxysmal atrial fibrillation, evaluated by continuous pre- and post-procedural heart rhythm monitoring. The second part consists of 20 patients with persistent or longstanding persistent atrial fibrillation following the same scheme. |
Radiofrequency catheter ablation of atrial fibrillation driving sources detected by sequential bi-atrial panoramic contact mapping.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Single procedure freedom from atrial fibrillation (AF) at 12 months.
Tidsramme: 12 months.
|
Freedom from AF defined as <1% AF burden as detected by the implanted heart rhythm monitor.
|
12 months.
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Single procedure freedom from atrial fibrillation (AF) at 24 months.
Tidsramme: 24 months.
|
Freedom from AF defined as <1% AF burden as detected by the implanted heart rhythm monitor.
|
24 months.
|
Single procedure freedom from atrial fibrillation (AF) at 30 months.
Tidsramme: 30 months.
|
Freedom from AF defined as <1% AF burden as detected by the implanted heart rhythm monitor.
|
30 months.
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Cumulative freedom from atrial fibrillation (AF) (multi-procedure).
Tidsramme: 30 months.
|
Cumulative freedom from AF (multi-procedure) measured from final study.
|
30 months.
|
Major procedure related events.
Tidsramme: 0 to 12 months.
|
Cardiac tamponade/perforation; stroke; transient ischemic attack; bleeding; vascular access complications; injury to the esophagus/phrenic or vagal nerve etc.
|
0 to 12 months.
|
Number of rotors identified and percentage eliminated on remap.
Tidsramme: Procedural.
|
Number of rotors identified and percentage eliminated on remap will be evaluated during the procedure.
|
Procedural.
|
Quality of life (QOL).
Tidsramme: 12 months.
|
QOL will be evaluated by the SF-36 health survey (Norwegian version) pre- and 12 months post ablation.
|
12 months.
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Rolf Franck Berntsen, MD, PhD, Dept. of Cardiology, Rikshospitalet - Oslo University Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2013/627
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Atrieflimmer
-
Pusan National University HospitalHar ikke rekruttert ennåHjerteimplanterbar elektronisk enhet | Atrial High Rate EpisodeKorea, Republikken
-
The Second Affiliated Hospital of Chongqing Medical...UkjentAtrieflimmer | Hjerteombygging, atrial | Sacubitril/Valsartan
-
W.L.Gore & AssociatesFullført
-
Helios Klinikum PforzheimRekrutteringHøyre hjertesvikt | Trikuspidal regurgitasjon | Hjerteombygging, Ventrikulær | Hjerteombygging, atrialTyskland
-
Henry Ford Health SystemTilbaketrukket
-
Nobles Medical Technologies II IncPåmelding etter invitasjonForamen Ovale, patent | Septal defekt, atrial | Septaldefekt, hjerteForente stater, Italia
-
HeartStitch.ComUkjentForamen Ovale, patent | Septal defekt, atrial | Septaldefekt, hjerteForente stater
-
China National Center for Cardiovascular DiseasesRekrutteringHjertesykdommer | Atrial septal dilatasjonKina
-
Assiut UniversityUkjent
-
Amsterdam UMC, location VUmcRekruttering
Kliniske studier på FIRM ablation
-
Cynosure, Inc.FullførtIkke-invasiv lipolyseForente stater
-
University of California, San DiegoNational Heart, Lung, and Blood Institute (NHLBI); National Institutes...RekrutteringAtrieflimmerForente stater
-
Abbott Medical DevicesAvsluttetParoksysmal atrieflimmerTyskland
-
Pentax MedicalFullførtColdplay kryoablasjon av dysplastisk plateepitelvev hos pasienter med esophageal plateepiteldysplasiEsophageal plateepiteldysplasiKina
-
Pentax MedicalFullførtEvaluering av effekten av CryoBalloon Focal Ablation System på Human Esophageal Barrett's EpitheliumBarretts spiserørForente stater, Nederland
-
Johns Hopkins UniversityRekrutteringKronisk smerte | Nakkesmerter | Cervical fasett leddsmerterForente stater
-
University of AdelaideBoston Scientific Corporation; Medtronic; Abbott Medical DevicesFullførtHjertefeil | AtrieflimmerAustralia, Storbritannia, New Zealand, Malaysia, Tyskland
-
University Hospital, ToulouseFullført
-
Mayo ClinicPentax MedicalFullført
-
Acutus MedicalTilbaketrukket